{
  "symbol": "IMRN",
  "company_name": "Immuron Ltd ADR",
  "ir_website": "https://www.immuron.com.au/invest-centre/",
  "structured_data": [
    {
      "section_name": "Analysts Reports",
      "links": [
        {
          "title": "Analysts Reports",
          "url": "https://www.immuron.com.au/analysts-reports/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733126855472464) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733126855904315)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-39)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-39)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-39)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-39)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Analysts Reports ](/analysts-reports/)\n\n\n\n# Analysts Reports \n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n  * ## [Immuron Limited – September Quarter 2024 Update – Litchfield Hills Research (October 2024)](https://www.immuron.com.au/assets/files/IMRN%203Q24%20Update%20Final.pdf)\n\n  * ## [Immuron Limited – Litchfield Hills Research - Initiation Report (September 2024)](https://www.immuron.com.au/assets/files/IMRN-initiation-Final.pdf)\n\n  * ## [Immuron Limited – Mecca Partners (September 2024)](https://www.immuron.com.au/assets/files/Immuron-Report_Arham%20Khan_09_2024.pdf)\n\n  * ## [Immuron Limited – Bioshares update (September 2024)](https://www.immuron.com.au/assets/files/Bioshares%20961%20IMC%20extract.pdf)\n\n  * ## [Immuron Limited FY24 Results Note – Henslow Research (September 2024)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron: Continually breaking sales records – Pitt Street Research (July 2024)](https://www.pittstreetresearch.com/immuron)\n\n  * ## [Immuron Limited 4Q24 Sales Update – Henslow Research (July 2024)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron Limited – Bioshares update (May 2024)](https://www.immuron.com.au/assets/files/Bioshares%20956%20IMC%20extract.pdf)\n\n  * ## [Immuron Limited 3Q24 Sales Update – Henslow Research (April 2024)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron: Soon to enter the ‘Phase 3 club’ – Pitt Street Research (March 2024)](https://www.pittstreetresearch.com/s/Immuron-research-update-20-03-24.pdf)\n\n  * ## [Immuron Limited 1H24 Results Note - Henslow Research (March 2024)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron Limited: Progressing fast with clinical trials (February 2024)](https://www.pittstreetresearch.com/s/Immuron-research-update-6-February-2024.pdf)\n\n  * ## [Immuron Limited 1H24 Sales Update - Henslow Research (January 2024)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron Limited: Immunity for the gut (November 2023)](https://www.immuron.com.au/assets/files/Immuron%20-%20Pitt%20Street%20report%20-%202%20November%20\\(21-Dec%20update\\).pdf)\n\n  * ## [Immuron Limited FY23 Results - Henslow Research (September 2023)](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron Limited Bioshares Report – (May 2023)](https://www.immuron.com.au/assets/files/Bioshares%20937%20IMC%20extract.pdf)\n\n  * ## [Immuron Limited 1H 2023 Results – Henslow Research (Mar 2023) ](https://henslow.com/news/research/immuron/)\n\n  * ## [Immuron Equity Report (Oct 2019)](/assets/files/Immuron%20ini%20TEquity%20-%20Oct%2019.pdf)\n\n  * ## [Immuron takes aim at the rapid growth of autoimmune diseases](https://smallcaps.com.au/immuron-takes-aim-rapid-growth-autoimmune-disease)\n\n  * ## [Immuron surges 28pc after study shows tablets fight Bali Belly in US soldiers (Jan 2018)](https://stockhead.com.au/health/immuron-surges-28pc-after-study-shows-tablets-fight-bali-belly-in-us-soldiers/)\n\n  * ## [Van ](http://immuron.com/assets/IMC-Leewnhoeck-Report-on-Immuron-13-Feb-2017.pdf)[Leeuwenhoeck](/assets/files/Van-Leeuwenhoeck-Institute-Updated-Report-Nov-2017.pdf)[ ](/assets/files/Van-Leeuwenhoeck-Institute-Updated-Report-Nov-2017.pdf)[Institute Updated Report (Nov 2017)](http://immuron.com/assets/Immuron-ini-Sept-2017.pdf)\n\n  * ## [Emerging Biologics in Fatty-Liver and Infectious Disease Management (Sep 2017)](/assets/files/Emerging%20Biologics%20in%20fatty-liver%20and%20infectious%20disease%20management.pdf)\n\n  * ## [BioShares Report - Edition 687 (Mar 2017)](/assets/files/BioShares-Edition-687-Report-on-Immuron-10-Mar-2017.pdf \" BioShares Edition 687 Report on Immuron 10 Mar 2017\")\n\n  * ## [Van Leeuwenhoeck Institute Report - Substantial Re-rating in NASH (Feb 2017)](/assets/files/IMC-Leewnhoeck-Report-on-Immuron-13-Feb-2017.pdf)\n\n  * ## [Van Leeuwenhoeck Institute Independent Research Note (Jan 2017)](/assets/files/Van-Leeuwenhoeck-Institute-VLI-Immuron-Research-Report-18-Jan-2017.pdf)\n\n  * ## [SeeThru Equity Analyst Report (Feb 2016)](/assets/files/IMC-AX-INITIATION-2-2-16-FINAL.PDF)\n\n  * ## [Red Chip C-Difficile Analyst Report (Jan 2016)](/assets/files/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf)\n\n  * ## [Red Chip Analyst Report (Aug 2015)](/assets/files/Red-Chip-Analyst-Report-17-August-2015.pdf)\n\n\n\n\n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Presentations",
      "links": [
        {
          "title": "Corporate Presentations",
          "url": "https://www.immuron.com.au/corporate-presentations/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733071622905026) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733071622911779)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Corporate Presentations](/corporate-presentations/)\n\n\n\n# Corporate Presentations\n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n20 Oct 2024 | Coffee Microcaps Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Investor%20Presentation%20-%2022%20October%202024.pdf)  \n---|---|---  \n08 Oct 2024 | The 22nd International Workshop on Campylobacter, Helicobacter & Related Organisms – Dr Frédéric Poly, NMRC | Download [here](https://www.immuron.com.au/assets/files/CampETEC_CHRO2024_V9.pdf)  \n25 Sep 2024 | Emerging Growth Conference 75 | Watch [here](https://www.youtube.com/watch?v=8KCWNvusHC0)  \n08 Sep 2024 | 18th Vaccine Congress Lisbon Portugal - Dr Mohamed Al-Ibrahim Senior Investigator, Pharmaron | Download [here](https://www.immuron.com.au/assets/files/Immuron%20IMM-124E-2002%20Vaccine%202024%20Lisbon%20Portugal.pdf)  \n08 Aug 2024 | Market Open Direct Connect webinar | Watch [here](https://www.youtube.com/watch?v=Z9vTsH3e5rQ)  \n31 Jul 2024 | TechKnow Invest Roadshow 2024 | Watch [here](https://www.youtube.com/watch?v=xQzeq_OpkMU)  \n18 Jul 2024 | Emerging Growth Conference 73 | Watch [here](https://youtu.be/N0ZGHrucK3U)  \n09 Jul 2024 | Sharewise | Watch [here](https://youtu.be/GZ4YxH9410Y)  \n20 Jun 2024 | GCFF Virtual 2024 – Bio Investing Conference (English) | Watch [here](https://youtu.be/u1D_67V7jls)  \n20 Jun 2024 | GCFF Virtual 2024 – Bio Investing Conference (Chinese) | Watch [here](https://youtu.be/NaL5D6k0hqM)  \n13 Jun 2024 | 2024 Emerging Growth Conference | Watch [here](https://youtu.be/idX1yZYvVlg)  \n01 May 2024 | JustStocks ‘Stars in 2024’ Investor Event | Watch [here](https://youtu.be/QISBfuehrMs?feature=shared)  \n30 Apr 2024 | Travelan® Bound for Phase 3 Clinical Trials | Watch [here](https://www.linkedin.com/events/travelan-boundforphase3clinical7180999382673018882/theater/)  \n23 Apr 2024 | The Watchlist | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Investor%20Presentation%20-%20The%20Watchlist%20\\(FYI-610432980\\).pdf)  \n14 Mar 2024 | Coffee Microcaps Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Coffee%20Microcaps.pdf)  \n21 Feb 2024 | Australian Biologics Festival 2024 | Download [here](https://www.immuron.com.au/assets/files/Australian%20Biologics%20Festival%202024.pdf)  \n08 Feb 2024 | Monsoon Communications Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Monsoon%20Investor%20Presentation_2%20\\(1\\).pdf)  \n30 Nov 2023 | Coffee Microcaps Webinar | Watch [here](https://youtu.be/wsOerX6-fFY?si=xEQXjFQiC_MazFDU)  \n03 Nov 2023 | Emerging ASX Gems Presentation | Watch [here](https://www.youtube.com/watch?v=0XJe0lYTJiw)  \n30 Oct 2023 | AusBioInvest Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20AusBioInvest%20-%20October%202023.pdf)  \n11 Sep 2023 | HCW Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20HCW%20-%20September%202023.pdf)  \n24 Jul 2023 | Bioshares Presentation | Download [here](https://www.immuron.com.au/assets/files/M112-Immuron.pdf)  \n06 Jun 2023 | LD Micro Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20LD%20Micro%20-%20June%202023.pdf)  \n02 May 2023 | Coffee Microcaps Investor Presentation | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Coffee%20Microcaps%20-%202%20May%202023.pdf)  \n19 Apr 2023 | Business Update | Watch [here](https://youtu.be/DlEvSaMmCu0)  \n19 Apr 2023 | Corporate Slide Deck | Download [here](https://www.immuron.com.au/assets/files/Immuron%20-%20Business%20Update%20-%2019%20April%202023.pdf)  \n  \n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Company Securities Exchange Announcements",
      "links": [
        {
          "title": "Company Securities Exchange Announcements",
          "url": "https://www.immuron.com.au/company-securities-exchange-announcements/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733077641220685) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733077641389931)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Company Securities Exchange Announcements](/company-securities-exchange-announcements/)\n\n\n\n# Company Securities Exchange Announcements\n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n..\n\n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Capital Structure & Register",
      "links": [
        {
          "title": "Capital Structure & Register",
          "url": "https://www.immuron.com.au/capital-structure-register/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733123966298949) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733123966280248)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-227)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-227)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-227)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-227)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Capital Structure & Register ](/capital-structure-register/)\n\n\n\n# Capital Structure & Register \n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n#### As at 2 September 2022\n\n[Capital Structure & Register](https://www.immuron.com.au/assets/files/IMC%20-%20Shareholder%20information%20-%20Sep%202022.pdf)\n\n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Directory and Governance",
      "links": [
        {
          "title": "Corporate Directory and Governance",
          "url": "https://www.immuron.com.au/corporate-directory-and-governance/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733094558011083) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733094558553031)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-180)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-180)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-180)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-180)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n\n\n\n# Corporate Directory and Governance \n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n[XBRL Interactive Data 30 June 2023 filed with the SEC](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1660046&accession_number=0001213900-23-080084&xbrl_type=v)\n\n[XBRL Interactive Data 30 June 2022 filed with the SEC](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1660046&accession_number=0001213900-22-054904&xbrl_type=v)\n\n[XBRL Interactive Data 30 June 2021 filed with the SEC](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1660046&accession_number=0001213900-21-055241&xbrl_type=v)\n\n[XBRL Interactive Data 30 June 2020 filed with the SEC](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1660046&accession_number=0001213900-20-033685&xbrl_type=v)\n\n[XBRL Interactive Data 30 June 2019 filed with the SEC](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1660046&accession_number=0001213900-19-021197&xbrl_type=v)\n\n[XBRL Interactive Data 30 June 2018 filed with the SEC](https://www.immuron.com.au/assets/imc-20180630.zip)\n\n[Annual Report 2023](https://imc.irmau.com/pdf/755e7481-96a0-4c3a-aca8-94b32b706984/Annual-Report-to-shareholders.pdf)\n\n[Annual Report 2022](https://www.asx.com.au/asxpdf/20220909/pdf/45dyg5jg380k7x.pdf)\n\n[Annual Report 2021](https://www.asx.com.au/asxpdf/20210930/pdf/4513k2m3dxzv2g.pdf)\n\n[Annual Report 2020](/assets/files/IMC%20Annual%20Report%202020.pdf)\n\n[Annual Report 2019](/assets/files/Annual%20Report%202019.pdf)\n\n[Annual Report 2018](/assets/files/1.%20Annual%20Report%20\\(Final\\)%202018.pdf)\n\n[Immuron Corporate Governance Charters & Policies ](https://www.immuron.com.au/assets/files/IMC%20-%20Corporate%20Governance%20Charters%20and%20Policies%202022%20\\(To%20upload%20to%20website\\).pdf)\n\n[Immuron Corporate Governance Statement 2023](https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02717622-3A627117)\n\n[Form 20-F filed with the SEC](https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=116215569&type=PDF&symbol=IMRN&companyName=Immuron+Limited&formType=20-F&formDescription=Annual+and+transition+report+of+foreign+private+issuers+%5BSections+13+or+15%28d%29%5D&dateFiled=2021-10-29&CK=1660046)\n\n[Immuron Limited Board Diversity Matrix - 2024 & 2023](https://www.immuron.com.au/assets/files/Immuron%20Limited%20-%20Board%20Diversity%20Matrix%20-%202024%20and%202023.pdf)\n\n### Share Registry\n\nSecurity Transfer Australia\n\n**Email** | registrar@securitytransfer.com.au  \n---|---  \n**Phone** | +61 (0) 8 9315 2333  \nMonday to Friday between 8:00am and 5:00pm WST  \n**Fax** | +61 (0) 8 9315 2233  \n**Postal Address** | PO Box 535, Applecross, WA 6953, Australia  \n**Street Address** | 770 Canning Highway, Applecross WA, 6153 Australia  \n  \n### Company Auditor\n\nGrant Thornton Audit Pty Ltd\n\nEmail | communications@au.gt.com  \n---|---  \nPhone | +61 (0)3 8320 2222  \nFax | +61 (0)3 8320 2222  \nStreet Address |  Collins Square, Tower 5 727 Collins Street Melbourne VIC 3008 Australia  \n  \n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Contacts",
      "links": [
        {
          "title": "Corporate Contacts",
          "url": "https://www.immuron.com.au/corporate-contacts/",
          "content": "  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Email Sign Up](https://immuron.us4.list-manage.com/subscribe?u=0b4c9c55a39d2ff3c9202c05f&id=2162e88238)\n  * [ ![](/assets/themes/2021-03-avtech-3115/img/asx_icons.png?1722407946) ](http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=imc&timeframe=D&period=M6)\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n[ ![Immuron](/assets/website_logo.png) ](https://www.immuron.com.au \"Immuron\")\n\n  * [ +613 8892 4854](tel:+613 8892 4854)\n  * info@immuron.com\n\n\n\n  * [ Cart - 0 ](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733123597457209) [](#)\n\n\n\n\n  * [ Menu](#)\n  * [ Shop](#)\n  * [ Cart (0)](https://www.immuron.com.au/_mycart?tkn=cart&ts=1733123597100437)\n  * [ Account](/_myacct/)\n\n\n\n  * [About Us](#mob-menu-0-227)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology](#mob-menu-1-227)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights](#mob-menu-2-227)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications](/scientific-publications/)\n  * [Investor Centre](#mob-menu-4-227)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us](/form/contact-us/)\n\n\n\n  * [](https://www.immuron.com.au \"Immuron\")\n  * [Products ](/products)\n    * [Travelan®](/travelan)\n    * [Protectyn®](/protectyn)\n  * [About Us ](/about-us/)\n    * [About Us](/about-us/)\n    * [Board of Directors ](/board-of-directors/)\n    * [Management Team](/management-team/)\n    * [Research Partners](/research-partners/)\n  * [Technology ](/technology-platform/)\n    * [Technology Platform](/technology-platform/)\n    * [Product Pipeline ](/product-pipeline/)\n    * [Intellectual Property](/intellectual-property/)\n    * [Production ](/production/)\n  * [Clinical Insights ](/blog/clinical-insights-updates/)\n    * [Commercial products](/commercial-products/)\n    * [Travelan US Army Research](/blog/clinical-insights-updates/travelan-us-army-research-and-clinical-studies-unp/)\n  * [Scientific Publications ](/scientific-publications/)\n  * [Investor Centre ](/invest-centre/)\n    * [Company Media ](/company-media/)\n    * [Newsletters](/company-media/newsletters/)\n    * [Analysts Reports ](/analysts-reports/)\n    * [Corporate Presentations](/corporate-presentations/)\n    * [Company Securities Exchange Announcements ](/company-securities-exchange-announcements/)\n    * [Capital Structure & Register ](/capital-structure-register/)\n    * [Corporate Directory and Governance ](/corporate-directory-and-governance/)\n    * [Corporate Contacts ](/corporate-contacts/)\n  * [Contact Us ](/form/contact-us/)\n\n\n  * [Travelan®](/travelan)\n  * [Protectyn®](/protectyn)\n\n\n\n### Categories\n\n  * [Products](https://www.immuron.com.au/products)\n\n\n\n### Information\n\n  * [About Us](/about-us)\n  * [Returns Policy](/returns_policy)\n  * [Contact Us](/form/contact-us)\n  * [Travelan® ](https://www.travelan.com/)\n  * [Protectyn®](http://protectyn.com.au/)\n\n\n\n  * [Home](https://www.immuron.com.au)\n  * [Investor Centre](/invest-centre/)\n  * [Corporate Contacts ](/corporate-contacts/)\n\n\n\n# Corporate Contacts \n\n![](/assets/pixel.gif) ![](/assets/pixel.gif)\n\n### **Company contact**\n\nMr Steven Lydeamore\n\nChief Executive Officer \n\nImmuron Limited\n\nPh: + 61 (0)3 9824 5254\n\n## Partners\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n![Footer Logo 4](/assets/marketing/60.png?1499923991)\n\n![Footer Logo 6](/assets/marketing/62.png?1499923858)\n\n![Feature Products 8](/assets/marketing/68.png?1499924239)\n\n![Footer 9](/assets/marketing/87.jpg?1603677395)\n\n[ ![Footer Logo 1](/assets/marketing/57.png?1499923729) ](#)\n\n![Footer Logo 2](/assets/marketing/58.png?1499923747)\n\n![Footer Logo 3](/assets/marketing/59.png?1499925925)\n\n#### Secure Shopping\n\nFully protected by Incapsula\n\n![](/assets/images/ssl-logo.png) ![](/assets/images/comodo-logo.png)\n\n#### Get Connected\n\nJoin our social networks\n\n  * [](http://linkedin.com/company/immuronltd)\n  * [](https://twitter.com/ImmuronLtd?lang=en)\n\n\n\n![](/assets/themes/2021-03-avtech-3115/img/footer_logo.png?1722407946)\n\nImmuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. \n\nThe company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.\n\nCopyright © 2024 Immuron \n\nE-commerce software by [Neto](https://www.netohq.com)\n\n#### About Us\n\n  * [About Us](/about-us)\n  * [Travelan](http://travelan.com/)\n  * [Protectyn](http://protectyn.com.au/)\n  * [Clinical Insights](/blog/clinical-insights-updates)\n  * [Contact Us](/form/contact-us)\n\n\n\n#### Information\n\n  * [Terms of Use](/website-terms-of-use/)\n  * [Privacy Policy](/privacy_policy)\n  * [Returns Policy](/returns_policy/)\n  * [Security Policy](/security_policy)\n\n\n\n#### Payment Options\n\n#### Contact Information\n\n  * Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia\n  * Phone: [+613 8892 4854](tel:+613 8892 4854)\n  * Fax: +613 9899 8533\n\n\n\n[](javascript:void\\(0\\);)\n"
        }
      ]
    }
  ]
}